Verseon Claims Major Move In Drug Design, Will Enter Clinic Within A Year
This article was originally published in The Pink Sheet Daily
Executive Summary
The Fremont, California-based company has developed a computer-driven discovery platform that can model drug-protein interactions with unparalleled accuracy but can also generate synthetic pathways for its drug candidates.
You may also be interested in...
In Silico Drug Design: Finally Ready For Prime Time?
Advances in computational power and in the application of quantum mechanics to drug modeling are rekindling interest in in silico drug design. The prize is a steep reduction in the cost of discovery and an increase in the quality of lead candidates.
European Biotech Is “Hot” Again, But Needs Nurturing For Further Growth
European biotech executives, entrepreneurs and investors are much more optimistic today about the sector’s growth prospects than just a few years ago – that’s despite lingering negatives like the region’s small number of mid-sized companies, a lack of investors willing to finance beyond seed and Series A rounds, and the relative dearth of executive talent.
Evotec Drug Development Strategy Offers Little Downside, Big Upside
Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.